Correlation
The correlation between ARCT and CNXC is 0.50, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
ARCT vs. CNXC
Compare and contrast key facts about Arcturus Therapeutics Holdings Inc. (ARCT) and Concentrix Corporation (CNXC).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: ARCT or CNXC.
Performance
ARCT vs. CNXC - Performance Comparison
Loading data...
Key characteristics
ARCT:
-0.88
CNXC:
-0.05
ARCT:
-0.99
CNXC:
0.38
ARCT:
0.89
CNXC:
1.05
ARCT:
-0.63
CNXC:
-0.06
ARCT:
-0.98
CNXC:
-0.15
ARCT:
59.22%
CNXC:
30.42%
ARCT:
74.24%
CNXC:
63.02%
ARCT:
-92.79%
CNXC:
-81.19%
ARCT:
-89.71%
CNXC:
-70.62%
Fundamentals
ARCT:
$345.25M
CNXC:
$3.68B
ARCT:
-$2.52
CNXC:
$3.99
ARCT:
2.40
CNXC:
0.38
ARCT:
1.37
CNXC:
0.90
ARCT:
$135.17M
CNXC:
$9.59B
ARCT:
$136.31M
CNXC:
$3.27B
ARCT:
-$60.17M
CNXC:
$1.17B
Returns By Period
In the year-to-date period, ARCT achieves a -24.99% return, which is significantly lower than CNXC's 34.45% return.
ARCT
-24.99%
-0.70%
-27.30%
-65.33%
-15.21%
-20.04%
N/A
CNXC
34.45%
11.62%
29.52%
-3.00%
-27.34%
N/A
N/A
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
ARCT vs. CNXC — Risk-Adjusted Performance Rank
ARCT
CNXC
ARCT vs. CNXC - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Arcturus Therapeutics Holdings Inc. (ARCT) and Concentrix Corporation (CNXC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
ARCT vs. CNXC - Dividend Comparison
ARCT has not paid dividends to shareholders, while CNXC's dividend yield for the trailing twelve months is around 2.26%.
| TTM | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
ARCT Arcturus Therapeutics Holdings Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
CNXC Concentrix Corporation | 2.26% | 2.87% | 1.15% | 0.77% | 0.14% |
Drawdowns
ARCT vs. CNXC - Drawdown Comparison
The maximum ARCT drawdown since its inception was -92.79%, which is greater than CNXC's maximum drawdown of -81.19%. Use the drawdown chart below to compare losses from any high point for ARCT and CNXC.
Loading data...
Volatility
ARCT vs. CNXC - Volatility Comparison
Arcturus Therapeutics Holdings Inc. (ARCT) has a higher volatility of 22.29% compared to Concentrix Corporation (CNXC) at 7.50%. This indicates that ARCT's price experiences larger fluctuations and is considered to be riskier than CNXC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
ARCT vs. CNXC - Financials Comparison
This section allows you to compare key financial metrics between Arcturus Therapeutics Holdings Inc. and Concentrix Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ARCT vs. CNXC - Profitability Comparison
ARCT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Arcturus Therapeutics Holdings Inc. reported a gross profit of 29.38M and revenue of 29.38M. Therefore, the gross margin over that period was 100.0%.
CNXC - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Concentrix Corporation reported a gross profit of 855.90M and revenue of 2.37B. Therefore, the gross margin over that period was 36.1%.
ARCT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Arcturus Therapeutics Holdings Inc. reported an operating income of -16.83M and revenue of 29.38M, resulting in an operating margin of -57.3%.
CNXC - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Concentrix Corporation reported an operating income of 168.87M and revenue of 2.37B, resulting in an operating margin of 7.1%.
ARCT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Arcturus Therapeutics Holdings Inc. reported a net income of -14.08M and revenue of 29.38M, resulting in a net margin of -47.9%.
CNXC - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Concentrix Corporation reported a net income of 70.26M and revenue of 2.37B, resulting in a net margin of 3.0%.